CClinicalTrials.gg
Sign In
RecruitingNCT04537390AMHUpdated Sep 3, 2026

Anti-mullerian Hormone Levels in Healthy Females

An interventional study of Blood sample collection in Healthy, sponsored by Erin Rowell. Recruiting at 1 site in United States. Open to female participants aged Up to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by Erin Rowell · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Registered 4 years 1 month after the study started (first participant enrolled Jul 2016, registered Aug 2020).
  • Started Jul 2016; still recruiting 10 years 2 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
Up to 18 Years
Sex
Female
01

Study summary

The purpose of this study is to have a better understanding of the normal blood levels of AMH in females from 0-18 years of age and how the blood AMH levels correspond to a female's reproductive development.

Read the detailed description

Anti-mullerian hormone (AMH) is a chemical in the body that is found in the blood that can estimate the ability of a female to have her own children. It is widely used in adult female cancer patients to predict the onset of menopause and/or the inability to have children that can be associated with chemotherapy and/or radiation treatment. Normal blood levels of AMH are better understood in adults than in children and adolescents. The purpose of this study is to have a better understanding of the normal blood levels of AMH in females from 0-18 years of age and how the blood AMH levels correspond to a female's reproductive development. With a better understanding of normal AMH levels in children, we may be able to better assess a girl's risk of not being able to have children if she is a cancer patient, and may be able to offer her and her family options to increase the chances of having her own children.

02

Conditions studied

  • Healthy

Keywords

  • AMH
03

In context

Lead sponsor

Erin Rowell is the lead sponsor of 4 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 18 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Pre- and post-pubertal females
  2. Ages 0-18 years old
  3. Tanner Stage I- V

  4. Undergoing routine outpatient surgical procedure

    1. Hernia repair (inguinal, umbilical, epigastric)
    2. Excision of benign mass
    3. laparoscopic cholecystectomy

Exclusion criteria

Exclusion Criteria:

  1. Previous diagnosis of an illness associated with premature ovarian failure (Turner's syndrome, Fragile X permutation carrier) or endocrine disorder associated with irregular menstrual cycles (Cushing's disease, poorly-controlled Thyroid disease, hyperprolactinemia, polycystic ovary syndrome, and congenital adrenal hyperplasia) or insulin-dependent diabetes mellitus or autoimmune disorders
  2. Previous diagnosis of any malignancy or any history of systemic/local chemotherapy, radiation therapy, or stem-cell transplant.
  3. Previous surgical excision of one ovary or both ovaries
  4. Pregnant females
  5. All inpatient surgical patients

  6. Undergoing non-routine outpatient surgical procedures

    1. Central venous catheter placement
    2. Supprelin insertion/removal
    3. Breast mass excision
    4. Gastrostomy tube insertion
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Other
    Blood sample collection

    Blood samples are collected for diagnostically assessing how the blood AMH levels correspond to a female's reproductive development

    Diagnostic Test: Blood sample collection

Interventions

  • Diagnostic testBlood sample collection

    Blood samples are collected for diagnostically assessing how the blood AMH levels correspond to a female's reproductive development

06

What researchers measure

Primary outcomes

  1. Anti-mullerian Hormone Levels in Healthy Females

    The primary outcome measure is to get a better understanding of the normal AMH levels in children (girls aged 0-18 years) in order to better assess a girl's risk of not being able to have children if she is a cancer patient, and in offering her and her family options to increase the chances of having her own children

    Time frame: 3 Years

07

Study locations

1 of 1 sites recruiting
  • Ann & Robert H Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04537390
Lead sponsor
Erin Rowell
Collaborators
Ann & Robert H Lurie Children's Hospital of Chicago
Responsible party
Erin Rowell (Director, Ann & Robert H Lurie Children's Hospital of Chicago) — Sponsor-investigator
First posted
Sep 3, 2020
Start date
Jul 19, 2016
Primary completion
Dec 1, 2030 (estimated)
Completion
Dec 1, 2030 (estimated)
Last update
Sep 3, 2026

Study contacts

Jacquelyn Searcy
Contact
FertilityPreservationMB@luriechildrens.org
3122274758
Erin Rowell, MD
principal investigator · Ann & Robert H Lurie Children's Hospital of Chicago

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Erin Rowell

Start the discussion